| Title |
Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, September 2018
|
| DOI | 10.1007/s00280-018-3683-8 |
| Pubmed ID | |
| Authors |
Z. Liu, J. Martin, L. Orme, B. Seddon, J. Desai, W. Nicholls, D. Thomson, D. Porter, G. McCowage, C. Underhill, N. Cranswick, M. Michael, M. Zacharin, A. Herschtal, J. Sivasuthan, D. M. Thomas |
| Abstract |
For many cancers, adolescents and young adults (AYA) have worse outcomes than for children and adults. Many factors may contribute to the AYA survival gap, including differences in biology, therapeutic intent, and adherence to therapy. It has been observed that male AYAs have poorer outcomes than females. The purpose of this work was to test the proposition that gender-related pharmacologic factors may account for a component of the AYA survival gap. A prospective, multi-institutional pharmacologic study of 79 patients in total with chemosensitive cancers (Ewing sarcoma, osteosarcoma and Hodgkin lymphoma) was conducted, with conventional doxorubicin treatment. Pharmacokinetic data of 13 children, 40 AYAs and 13 adults were valid for analysis. Population pharmacokinetics models were developed for doxorubicin and its metabolite doxorubicinol based on the data created in this study. Consequently, model-based analysis was conducted to investigate the relevant topics. The clearance of doxorubicinol (normalized to body surface area), the main active metabolite of doxorubicin, appears faster in male AYAs than female (p = 0.04, 95% CI 0.1-3.9 L/h). The exposure of doxorubicinol (normalized to dose) is lower in male AYA than female (p = 0.03, 95% CI - 0.005 to - 0.0002 h/L). These might be correlated to the observed difference on nadir neutrophil count between male AYA and female (p = 0.027, 95% CI 0.09-1.4). Gender-related differences in doxorubicin pharmacology may account for worse outcomes for male AYAs with chemosensitive cancers compared to females. These findings may reduce the AYA survival gap compared to other age groups. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 33% |
| Australia | 2 | 22% |
| Unknown | 4 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 67% |
| Scientists | 2 | 22% |
| Science communicators (journalists, bloggers, editors) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 20% |
| Student > Master | 6 | 20% |
| Researcher | 5 | 17% |
| Student > Ph. D. Student | 2 | 7% |
| Student > Postgraduate | 2 | 7% |
| Other | 1 | 3% |
| Unknown | 8 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 6 | 20% |
| Medicine and Dentistry | 6 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 17% |
| Nursing and Health Professions | 1 | 3% |
| Sports and Recreations | 1 | 3% |
| Other | 3 | 10% |
| Unknown | 8 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 July 2021.
All research outputs
#5,753,393
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#537
of 2,501 outputs
Outputs of similar age
#97,183
of 338,955 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#5
of 25 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,955 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.